

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/AU05/000141

International filing date: 03 February 2005 (03.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: AU

Number: 2004900471

Filing date: 03 February 2004 (03.02.2004)

Date of receipt at the International Bureau: 22 February 2005 (22.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



Australian Government


Patent Office
Canberra

I, JANENE PEISKER, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. 2004900471 for a patent by PETER HAMILTON KAY as filed on 03 February 2004.

I further certify that the above application is now proceeding in the name of RED RABBIT PTY LTD pursuant to the provisions of Section 113 of the Patents Act 1990.

WITNESS my hand this
Fourteenth day of February 2005

JANENE PEISKER
TEAM LEADER EXAMINATION
SUPPORT AND SALES



AUSTRALIA

Patents Act 1990

PROVISIONAL SPECIFICATION

Applicant(s) :

PETER HAMILTON KAY

Invention Title:

METHOD OF IDENTIFYING GENES WHICH PROMOTE HYBRID VIGOUR AND HYBRID DEBILITY AND USES THEREOF

The invention is described in the following statement:

METHOD OF IDENTIFYING GENES WHICH PROMOTE HYBRID VIGOUR
AND HYBRID DEBILITY AND USES THEREOF

FIELD OF THE INVENTION

5

The invention relates to a method of identifying candidate genes that are potentially useful in the diagnosis and treatment of disease and/or inducement of hybrid vigour. The invention further relates to the use of hybrid mRNA molecules produced *in vivo* to overcome disease in a plant or animal and/or fix the heritability of hybrid vigour or other biologically advantageous phenotype in a plant or animal.

15 BACKGROUND OF THE INVENTION

It has been recognised for many years that some genetic factors which have the capacity to influence growth, viability or robustness of plants, animals and other 20 organisms are more influential in offspring of genetically unrelated biologically normal parents. This biological phenomenon is referred to as hybrid vigour (HV) or heterosis (Milborrow, J. Exp. Bot. 49,1063 (1998); Gordon, Heredity 83, 757 (1999)). Offspring of genetically non- 25 identical parents are referred to as heterozygous organisms.

Although many theories have been advanced to explain this phenomenon, of major commercial importance, the view has 30 long been held that HV is driven by novel proteins (such as hormones, enzymes or growth factors) synthesised uniquely in heterozygous or hybrid organisms compared to either parent (Schwartz, Proc. Natl. Acad. Sci. U.S.A. 46, 1210 (1960); Gill, in Genetics and Wheat Improvement, A.K. 35 Gupta, Ed. (Oxford and IBH Publishing Co. New Delhi, 1977) pp 204-207), as found for example in the B37 x Mo17 maize hybrid (Romagnoli et al., Theor. Appl. Genet. 80, 769

(1990).

A further well known form of HV, in which an almost normal biological phenotype is restored in offspring of
5 biologically defective parents, each of which carry different mutational forms of the same gene is referred to as intragenic or interallelic complementation (IC).

Some of the novel proteins formed in heterozygous
10 offspring may, in contrast to HV, reduce the robustness, viability or well-being of an offspring compared to either parent. We refer to this biological phenotype as hybrid debility (HD⁰).

15 Because the ability to synthesise novel proteins in heterozygous organisms does not conform to a Mendelian mode of inheritance, the heritability of HV has been impossible to predict reliably.

20 Thus far the molecular genetic mechanism underlying the formation of novel proteins in heterozygous organisms is unknown.

It is known that proteins are synthesised under the
25 instruction of the inherited DNA sequence of genes through a series of well known biochemical steps. These steps comprise gene transcription, in which a primary RNA molecule (including intronic derived structures) is read off from the DNA sequence of genes inherited from each
30 parent. Non-coding or intron derived structures within the primary RNA molecule are spliced out by a large nucleoprotein complex called the spliceosome leaving only the coding or exonic derived regions. The remaining exon-derived regions are then fused to form a mature messenger
35 RNA (mRNA) molecule. The mRNA molecule then finally instructs the formation and amino acid sequence of a primary polypeptide by a process called translation.

It is thought that following gene transcription the spliceosome engages a primary RNA molecule and removes its intron-derived elements by a mono-molecular threading or 5 linear scanning process. Thus, exon-derived elements from the same primary RNA molecule are thought to be assembled to form mRNA in an orderly and well defined series of cis-reactions (Aebi et al. Trends Genet. 3, 102 (1987); Brown et al., Antonie van Leeuwenhoek 62, 35 (1992)).

10 In order to synthesise novel polypeptides or proteins, inventors have postulated that during the process of splicing, hybrid mRNA molecules could be generated *in vivo* by a primary RNA splicing mechanism that allows ligation 15 of the 3' end of an exon from a gene inherited from one parent with the 5' end of the next downstream exon from the same gene from the other parent. Thus, inventors hypothesise that novel or hybrid mRNA molecules from which 20 novel proteins can be synthesised, are generated by a previously unrecognised biochemical pathway which incorporates exons from each of the two different parental alleles into the same mature mRNA molecule. As detailed below, inventors have proven the existence of a biological pathway that assembles the said hybrid mRNA constructs.

25

SUMMARY OF THE INVENTION

The broadest aspect of the present invention provides a method of identifying candidate genes that are potentially 30 useful in the diagnosis and treatment of disease and/or fixing the heritability of HV or other biologically advantageous phenotype.

A first aspect provides a method for identifying candidate 35 genes capable of producing hybrid vigour in an animal or plant, comprising the steps of:

- (i) comparing the nucleotide sequence of

alleles of candidate genes isolated from an animal or plant which exhibits hybrid vigour with the nucleotide sequences from the corresponding alleles isolated from the parents of said animal or plant; and

5 (ii) identifying nucleotide sequence differences in the alleles from said animal or plant which exhibits hybrid vigour which codes for amino acid sequence variation.

10 (iii) identifying that the amino acid sequence variation between alleles of the candidate gene in said animal or plant is encoded by nucleotide sequences which are located within two or more different exons within the candidate gene.

15 A second aspect provides a method for identifying candidate genes capable of producing disease in an animal or plant, comprising the steps of:

20 (i) comparing the nucleotide sequence of alleles isolated from an animal or plant which exhibits said disease with the nucleotide sequences from the corresponding alleles isolated from the parents of said animal or plant; and

25 (ii) identifying nucleotide sequence differences in the alleles from said animal or plant which exhibits said disease which codes for amino acid sequence variation.

30 (iii) identifying that the amino acid sequence variation between alleles of the candidate gene in said animal or plant is encoded by nucleotide sequences which are located within two or more different exons within the candidate gene.

A third aspect provides a method for producing hybrid vigour in an animal or plant, comprising the steps of:

35 (i) comparing the nucleotide sequence of alleles isolated from a gene from an animal or plant which promotes hybrid vigour with the nucleotide sequences from

the corresponding alleles isolated from the parents of said animal or plant;

(ii) identifying nucleotide sequence differences in the alleles from said animal or plant which promote 5 hybrid vigour which code for amino acid sequence variation.

(iii) identifying that the amino acid sequence variation between alleles of the candidate gene in said animal or plant is encoded by nucleotide sequences which 10 are located within two or more different exons within the candidate gene.

(iv) preparing a construct comprising nucleotide sequence from the alleles which promotes hybrid vigour within said animal or plant;

15 (v) transforming said construct into a recipient plant or animal cell;

(vi) regenerating a plant or animal, which expresses said construct, from said cell.

20 A fourth aspect provides a method of detecting the presence or absence of hybrid mRNA in a plant or animal comprising the step of isolating mRNA from a plant or animal and comparing the nucleotide sequence of said mRNA to the corresponding coding sequence of the plant or 25 animal's alleles.

A fifth aspect provides a construct comprising a synthetic gene comprising exons from different alleles of a gene, wherein said alleles code for amino acid sequence 30 variation, wherein the variation occurs between different alleles.

The present invention further relates to the use of hybrid mRNA molecules produced *in vivo* to overcome disease in a 35 plant or animal and/or induce hybrid vigour in a plant or animal.

The plant cell may be isolated from any higher plant, including gymnosperms, monocotyledonous and dicotyledonous plants, although all agriculturally important plant species are preferred. Preferably, the plant cell is

5 isolated from a plant selected from the group consisting of barley, rye, sorghum, maize, soybean, wheat, corn, potato, cotton, rice, oilseed rape (including canola), sunflower, alfalfa, sugarcane, banana, blackberry, blueberry, strawberry, and raspberry, cantaloupe, carrot,

10 cauliflower, coffee, cucumber, eggplant, grapes, honeydew, lettuce, mango, melon, onion, papaya, peas, peppers, pineapple, spinach, squash, sweet corn, tobacco, tomato, watermelon, rosaceous fruits (such as apple, peach, pear, cherry and plum) and vegetable brassicas (such as

15 broccoli, cabbage, cauliflower, brussel sprouts and kohlrabi). Other crops, fruits and vegetables whose phenotype may be changed include barley, currant, avocado, citrus fruits such as oranges, lemons, grapefruit and tangerines, artichoke, cherries, nuts such as the walnut

20 and peanut, endive, leek, roots, such as arrowroot, beet, cassava, turnip, radish, yam, sweet potato and beans. Other plant cells that might used in the present invention include cells isolated from woody species, such pine, poplar and eucalyptus. More preferably, the plant cell is

25 a rice cell, a wheat cell, a barley cell, a rye cell, a sorghum cell or a maize cell.

The step of transforming the plant cell comprises any method known in the art, which is capable of stably

30 transforming the plant cell. Suitable protocols are available for Leguminosae (alfalfa, soybean, clover, etc.), Umbelliferae (carrot, celery, parsnip), Cruciferae (cabbage, radish, rapeseed, broccoli, etc.),

35 Curcurbitaceae (melons and cucumber), Gramineae (wheat, corn, rice, barley, millet, etc.), Solanaceae (potato, tomato, tobacco, peppers, etc.), and various other crops. See protocols described in Ammirato et al. (1984) Handbook

of Plant Cell Culture--Crop Species. Macmillan Publ. Co. Shimamoto et al. (1989) Nature 338:274-276; Fromm et al. (1990) Bio/Technology 8:833-839; and Vasil et al. (1990) Bio/Technology 8:429-434.

5

Preferably, the plant cell is transformed by a method selected from the group consisting of microprojectile bombardment, PEG mediated transformation of protoplasts, electroporation, silicon carbide fibre mediated transformation, or Agrobacterium-mediated transformation. In a preferred embodiment of the invention the step of transforming comprises microprojectile bombardment by coating microprojectiles with DNA comprising the construct and contacting the recipient cells with the microprojectiles.

10

In another aspect, the invention provides a method of producing progeny comprising the steps of (a) preparing a plant according to the methods described above; and (b) 20 crossing the plant with a second plant or with itself.

25

In yet another aspect, the invention provides a method of plant breeding comprising the steps of: (a) obtaining a progeny plant of any generation of a plant prepared according to the methods described above, wherein the 30 progeny plant comprises said construct; and (b) crossing the plant with itself or a second plant.

35

In a sixth aspect the invention provides a method for producing genetically engineered or transgenic animal by inserting a synthetic gene into a somatic cell or cell nucleus prior to transferring the somatic cell or cell nucleus, wherein said synthetic gene comprises exons from different alleles of a gene, wherein said alleles code for amino acid sequence variation, wherein the variation does not occur in the same allele.

The invention further provides genetically engineered or transgenic animal obtained by the method of the sixth aspect.

5 The animal cells can be isolated from any animal although it is particularly useful for mammals and fish. Suitable mammalian sources include members of the Orders Primates, Rodentia, Lagomorpha, Cetacea, Carnivora, Perissodactyla and Artiodactyla. Members of the Orders Perissodactyla
10 and Artiodactyla are particularly preferred because of their similar biology and economic importance.

For example, Artiodactyla comprise approximately 150 living species distributed through nine families: pigs
15 (Suidae), peccaries (Tayassuidae), hippopotamuses (Hippopotamidae), camels (Camelidae), chevrotains (Tragulidae), giraffes and okapi (Giraffidae), deer (Cervidae), pronghorn (Antilocapridae), and cattle, sheep, goats and antelope (Bovidae). Many of these animals are
20 used as feed animals in various countries. More importantly, with respect to the present invention, many of the economically important animals such as goats, sheep, cattle and pigs have very similar biology and share high degrees of genomic homology.

25 The Order Perissodactyla comprises horses and donkeys, which are both economically important and closely related. Indeed, it is well known that horses and donkeys interbreed.

30 In one embodiment, the animal cells will be obtained from an ungulate. Preferably, the ungulate is selected from the group consisting of domestic or wild representatives of bovids, ovids, cervids, suids, equids and camelids.
35 Examples of such representatives are cows or bulls, bison, buffalo, sheep, big-horn sheep, horses, ponies, donkeys, mule, deer, elk, caribou, goat, water buffalo, camels,

llama, alpaca, and pigs. Especially preferred in the bovine species are *Bos taurus*, *Bos indicus*, and *Bos buffaloes* cows or bulls.

- 5 In one embodiment the animal cells are isolated from aquatic organisms such as vertebrate and invertebrate marine animals. More preferably the aquatic organism is selected from the group consisting of fish, amphibians and molluscs. Fish include; but are not limited to,
- 10 zebrafish, European carp, salmon, mosquito fish, tench, lampreys, round gobies, tilapia and trout. Amphibians include; but are not limited to, toads and frogs. Molluscs include; but are not limited to, Pacific oysters, zebra mussels, striped mussels, New Zealand screw shells, the
- 15 Golden Apple Snail, the Giant African Snail, and the disease vectoring snails in the genera *Biomphalaria* and *Bulinus*.

Transformation of constructs of the invention into animal cells is preferably by electrofusion. Electrofusion is preferably induced by application of an electrical pulse across the contact/fusion plane. More preferably, the electrofusion comprises the step of delivering one or more electrical pulses.

25

DETAILED DESCRIPTION OF THE INVENTION

All publications mentioned herein are cited for the purpose of describing and disclosing the protocols and reagents which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

35

The practice of the present invention employs, unless otherwise indicated, conventional molecular biology, plant

and animal biology, and recombinant DNA techniques within the skill of the art. Such techniques are well known to the skilled worker, and are explained fully in the literature. See, eg., Maniatis, Fritsch & Sambrook,

5 "Molecular Cloning: A Laboratory Manual" (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover, Ed., 1985); "Oligonucleotide Synthesis" (M.J. Gait, Ed., 1984); "Nucleic Acid Hybridization" (B.D. Hames & S.J. Higgins, eds., 1985); "Transcription and

10 Translation" (B.D. Hames & S.J. Higgins, eds., 1984); B. Perbal, "A Practical Guide to Molecular Cloning" (1984), and Sambrook, et al., "Molecular Cloning: a Laboratory Manual" 12th edition (1989).

15 The description that follows makes use of a number of terms used in recombinant DNA technology. Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following

20 references provide one of skill with a general definition of many of the terms used in this invention: Singleton, et al., "Dictionary of Microbiology and Molecular Biology" (2nd ed. 1994); "The Cambridge Dictionary of Science and Technology" (Walker ed., 1988); "The Glossary of Genetics"

25 5th Ed., Rieger, R., et al. (eds.), Springer Verlag (1991); and Hale & Marham, "The Harper Collins Dictionary of Biology" (1991). Generally, the nomenclature and the laboratory procedures in plant and animal maintenance and breeding as well as recombinant DNA technology described

30 herein are those well known and commonly employed in the art.

It is understood that the invention is not limited to the particular materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and it is not intended to limit the

scope of the present invention which will be limited only by the appended claims. It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a plant cell" includes a plurality of such plant cells, and a reference to "an animal cell" is a reference to one or more animal cells. Although any materials and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred materials and methods are now described.

DEFINITIONS

15

The terms "polynucleotide", "polynucleotide sequence", "nucleic acid sequence", and "nucleic acid fragment"/"isolated nucleic acid fragment" are used interchangeably herein. These terms encompass nucleotide sequences and the like. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof

The term "isolated" polynucleotide refers to a polynucleotide that is substantially free from other nucleic acid sequences, such as and not limited to other chromosomal and extrachromosomal DNA and RNA that normally accompany or interact with the isolated polynucleotide as found in its naturally occurring environment. Isolated polynucleotides may be purified from a host cell in which they naturally occur. Conventional nucleic acid purification methods known to skilled artisans may be used to obtain isolated polynucleotides. The term also embraces recombinant polynucleotides and chemically synthesised

polynucleotides.

The term "recombinant" means, for example, that a nucleic acid sequence is made by an artificial combination of two 5 otherwise separated segments of sequence, eg., by chemical synthesis or by the manipulation of isolated nucleic acids by genetic engineering techniques.

As used herein, "substantially similar" refers to nucleic 10 acid molecules wherein changes in one or more nucleotide bases either results in no change to the amino acid sequence coded or substitution of one or more amino acids does not affect the functional properties of the polypeptide encoded by the nucleotide sequence.

15 Substantially similar nucleic acid molecules may also be characterised by their ability to hybridise. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridisation under conditions of stringency as is well 20 understood by those skilled in the art (Hames and Higgins, Eds. (1985) Nucleic Acid Hybridisation, IRL Press, Oxford, U.K.). Post-hybridisation washes determine stringency conditions. One set of preferred conditions uses a series 25 of washes starting with 6 X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2 X SSC, 0.5% SDS at 45°C. for 30 min, and then repeated twice with 0.2 X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the 30 temperature of the final two 30 min washes in 0.2 X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0.1 X SSC, 0.1% SDS at 65°C.

35 "Synthetic gene" or "synthetic nucleic acid fragments" can be assembled from oligonucleotide building blocks that are chemically synthesised using procedures known to those

skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid molecules, which may then be enzymatically assembled to construct the entire desired nucleic acid molecule. "Chemically synthesised", 5 as related to a nucleic acid fragment, means that the component nucleotides were assembled in vitro. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of 10 a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimisation of the nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful 15 gene expression if codon usage is biased towards those codons favoured by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

20 "Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. 25 "Chimeric gene" or "exogenous gene" are used herein interchangeably and refer to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric or exogenous gene may comprise regulatory sequences and 30 coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. 35 A "foreign-gene" refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise

native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

5 "Coding sequence" refers to a nucleotide sequence that codes for a specific amino acid sequence. "Regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which

10 influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

15 "Promoter" refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists

20 of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the

25 level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or may be composed of different elements derived from different promoters found in nature, or may even comprise synthetic nucleotide segments. It is understood by those skilled in

30 the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types

35 at most times are commonly referred to as "constitutive promoters".

"Translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the 5 translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) Mol. Biotechnol. 10 3:225-236). "3' non-coding sequences" refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation 15 signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) Plant Cell 1:671-680.

20 "RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript 25 or it may be a RNA sequence derived from post-transcriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into polypeptides by the cell. "cDNA" refers to 30 DNA that is complementary to and derived from an mRNA template. The cDNA can be single-stranded or converted to double stranded form using, for example, the Klenow fragment of DNA polymerase I. "Sense-RNA" refers to an RNA transcript that includes the mRNA and so can be translated 35 into a polypeptide by the cell. "Functional RNA" refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular

processes.

The term "operably linked" refers to the association of two or more nucleic acid fragments on a single 5 polynucleotide so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the 10 promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) 15 derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide.

A "protein" or "polypeptide" is a chain of amino acids 20 arranged in a specific order determined by the coding sequence in a polynucleotide encoding the polypeptide. Each protein or polypeptide has a unique function.

"Altered levels" or "altered expression" refers to the 25 production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

"Mature protein" or the term "mature" when used in 30 describing a protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor protein" or the term "precursor" when used in describing a protein refers to 35 the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization

signals.

"Transformation" refers to the transfer of a nucleic acid fragment into the genome of host organism, resulting in 5 genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. Examples of methods of plant transformation include Agrobacterium-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 10 143:277) and particle-accelerated or "gene gun" transformation technology (Klein et al. (1987) *Nature* (London) 327:70-73; U.S. Pat. No. 4,945,050, incorporated herein by reference). Thus, isolated polynucleotides of the present invention can be incorporated into recombinant 15 constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Such a construct can be a vector that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given 20 host cell. A number of vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants have been described in, e.g., Pouwels et al., *Cloning Vectors: A Laboratory Manual*, 1985, supp. 1987; Weissbach and Weissbach, *Methods for Plant Molecular 25 Biology*, Academic Press, 1989; and Flevin et al., *Plant Molecular Biology Manual*, Kluwer Academic Publishers, 1990. Typically, plant expression vectors include, for example, one or more cloned plant genes under the transcriptional control of 5' and 3' regulatory sequences 30 and a dominant selectable marker. Such plant expression vectors also can contain a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmentally- or developmentally- regulated, or cell- or tissue-specific expression), a 35 transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

"PCR" or "polymerase chain reaction" is well known by those skilled in the art as a technique used for the amplification of specific DNA segments (U.S. Pat. Nos. 5 4,683,195 and 4,800,159).

The term "progeny" refers to any subsequent generation, including the seeds and plants therefrom, which is derived from a particular parental plant or set of parental 10 plants.

"Regeneration" is the process of growing a plant from a plant cell (eg., plant protoplast or explant).

15 "Selected DNA" is a segment of DNA which has been introduced into a host genome. Preferred selected DNAs will include one or more exogenous genes and the elements for expressing an exogenous gene in a host cell, for example, a promoter and a terminator. Benefit may be 20 realised by including one or more enhancer elements with the selected DNA.

A "transformed cell" is a cell whose DNA has been altered by the introduction of an exogenous DNA molecule into that 25 cell.

A "transgenic plant" is a plant or progeny of any subsequent generation derived therefrom, of a transformed plant cell or protoplast, wherein the plant DNA contains 30 an introduced exogenous DNA molecule not originally present in a native, non-transgenic plant of the same strain. The transgenic plant may additionally contain sequences which are native to the plant being transformed, but wherein the "exogenous" gene has been altered by gene 35 technological means in order to alter the level or pattern of expression of the gene.

A "vector" is a DNA molecule capable of replication in a host cell and/or to which another DNA segment can be operatively linked so as to bring about replication of the attached segment. A plasmid is an exemplary vector or a

5 DNA molecule used to carry new genes into cells. A plasmid is an exemplary vector which is an independent, stable, self-replicating piece of DNA

10 As used herein, the term "genotype" means the genetic makeup of an individual cell, cell culture, plant or animal.

15 As used herein, the term "heterozygote" means a diploid or polyploid individual cell or plant or animal having different alleles (forms of a given gene) at least at one locus.

20 As used herein, the term "heterozygous" means the presence of different alleles (forms of a given gene) at a particular gene locus.

As used herein, the term "homozygote" means an individual cell or plant having the same alleles at one or more loci.

25 As used herein, the term "homozygous" means the presence of identical alleles at one or more loci in homologous chromosomal segments.

EXPERIMENTAL PROTOCOLS

30 One aspect of the invention relates to a method of identifying candidate genes. The term "candidate gene" refers to a gene or genes that are capable of producing hybrid vigour. The terms "hybrid vigour" or "heterosis" 35 are used herein interchangeably and means an increase in the performance of hybrids over that of purebreds, most noticeably in traits like fertility and disease

resistance. In particular the candidate genes are those genes, which are heterozygous and functional in one animal or plant and which lead to hybrid vigour. In one embodiment the alleles of each gene will comprise

5 nucleotide sequence variation in different exons of the coding sequence, wherein the variations lead to amino acid sequence variation. For example, if a plant or animal comprises two alleles of gene X ie heterozygote for gene X, it satisfies the first requirement as a candidate gene

10 of the present invention. A second criterion would be sequence variation in the nucleotide sequence, which variation leads to amino acid sequence variation in any expressed protein. A third criterion would be that each allele contains sequence variation, wherein the sequence

15 variation is not found at the same position in each allele. For example, in gene X *supra* each allele may contain a sequence variation wherein in allele 1 the variation is at position 1, while in allele 2 the variation is at position 20. This would satisfy the 2nd and 3rd criteria if the variation leads to a change in the amino acid sequence. A fourth criterion would be the variations appearing in different exons rather than merely in different positions within the same exon.

25 In one embodiment, the candidate gene would have one or more nucleotide sequence variations, which code for amino acid variations, wherein the variations are found in different exons on different alleles.

30 The candidate genes would preferably produce mRNA of at least three species: one mRNA molecule which is identical to one allele, one that was identical to the coding sequence of the second allele and one that comprised a combination of exons from both alleles. Obviously

35 depending upon the number of exons the number of different species of mRNA would be numerous.

Methods of identifying candidate genes would be relatively simple these could be identified by routine sequence analysis or Southern blot analysis of PCR amplified segments of candidate genes (see, for example, Gieselmann et al. (1989, Proc. Natl. Acad. Sci. U.S.A. 86:9436-9440). It will also be appreciated by those skilled in the art that detection of amplification in homogenous and/or closed tubes can be carried out using numerous means in the art, for example using TaqMan® hybridisation probes in the PCR reaction and measurement of fluorescence specific for the target nucleic acids once sufficient amplification has taken place. However, because of the nature and speed of the Roche Lightcycler®, the preferred method is by using real-time PCR and melting curve analysis on the Roche Lightcycler® using fluorescent labelled hybridisation oligonucleotides.

Although those skilled in the art will be aware that other similar quantitative "real-time" and homogenous nucleic acid amplification/detection systems exist such as those based on the TaqMan approach (US patent Nos 5,538,848 and 5,691,146), fluorescence polarisation assays (eg Gibson et al., Clin Chem, 1997; 43: 1336-1341), and the Invader assay (eg Agarwal P et al., Diagn Mol Pathol 2000 Sep; 9(3): 158-164; Ryan D et al, Mol Diagn 1999 Jun; 4(2): 135-144). Such systems would also be adaptable to use the invention described, enabling real-time monitoring of nucleic acid amplification and allele discrimination for detection of gene mutations and polymorphisms if appropriately designed.

Once a candidate gene has been identified it can then be isolated or produced synthetically to be used in other aspects of the invention. For example, a candidate gene, which is suspected of producing hybrid vigour, could be transformed into a host cell (plant or animal) and a transgenic plant or animal regenerated.

Methods for generating transgenic animal cells typically include the steps of (1) assembling a suitable DNA construct useful for inserting a specific DNA sequence into the nuclear genome of a cell; (2) transfecting the DNA construct into the cells; (3) allowing random insertion and/or homologous recombination to occur. The modification resulting from this process may be the insertion of a suitable DNA construct(s) into the target genome; deletion of DNA from the target genome; and/or mutation of the target genome.

DNA constructs can comprise a gene of interest, for example, a synthetic gene comprising exons taken from different alleles, wherein different exons comprise different sequences, as well as a variety of elements including regulatory promoters, insulators, enhancers, and repressors as well as elements for ribosomal binding to the RNA transcribed from the DNA construct. These examples are well known to a person of ordinary skill in the art and are not meant to be limiting.

Due to the effective recombinant DNA techniques available in conjunction with DNA sequences for regulatory elements and genes readily available in data bases and the commercial sector, a person of ordinary skill in the art can readily generate a DNA construct appropriate for establishing transgenic animal cells using the materials and methods described herein.

For example, if the entire nucleotide coding sequence for a candidate gene is not obtained in a single cDNA, genomic DNA, or other DNA, as determined, for example, by DNA sequencing or restriction endonuclease analysis, then appropriate DNA fragments (eg., restriction fragments or PCR amplification products) may be recovered from several DNAs and covalently joined to one another to construct the

entire coding sequence. The preferred means of covalently joining DNA fragments is by ligation using a DNA ligase enzyme, such as T4 DNA ligase. The isolated candidate gene can then be incorporated into a plasmid or expression vector.

Transfection techniques for animal cells are well known to a person of ordinary skill in the art and materials and methods for carrying out transfection of DNA constructs into animal cells are commercially available. Materials typically used to transfect animal cells with DNA constructs are lipophilic compounds, such as Lipofectin™ for example. Particular lipophilic compounds can be induced to form liposomes for mediating transfection of the DNA construct into the cells.

Target sequences from the DNA construct can be inserted into specific regions of the nuclear genome by rational design of the DNA construct. These design techniques and methods are well known to a person of ordinary skill in the art. See, for example, U.S. Patent 5,633,067; U.S. Patent 5,612,205 and PCT publication WO93/22432, all of which are incorporated by reference herein in their entirety. Once the desired DNA sequence is inserted into the nuclear genome, the location of the insertion region as well as the frequency with which the desired DNA sequence has inserted into the nuclear genome can be identified by methods well known to those skilled in the art.

Once the transgene is inserted into the nuclear genome of a donor cell, that cell, like other donor cells of the invention, can be used as a nuclear donor in nuclear transfer methods. The means of transferring the nucleus of a cell into an oocyte preferably involves cell fusion to form a reconstituted cell.

Fusion is typically induced by application of a DC electrical pulse across the contact/fusion plane, but additional AC current may be used to assist alignment of donor and recipient cells. Electrofusion produces a pulse of electricity that is sufficient to cause a transient breakdown of the plasma membrane and which is short enough that the membrane reforms rapidly. Thus, if two adjacent membranes are induced to breakdown and upon reformation the lipid bilayers intermingle, small channels will open between the two cells. Due to the thermodynamic instability of such a small opening, it enlarges until the two cells become one. Reference is made to U.S. Pat. No. 4,997,384 by Prather et al., (incorporated by reference in its entirety herein) for a further discussion of this process. A variety of electrofusion media can be used including eg., sucrose, mannitol, sorbitol and phosphate buffered solution.

Fusion can also be accomplished using Sendai virus as a fusogenic agent (Graham, Wister Inot. Symp. Monogr., 9, 19, 1969). Fusion may also be induced by exposure of the cells to fusion-promoting chemicals, such as polyethylene glycol.

Preferably, the donor animal cell and oocyte are placed in a 500 μ m fusion chamber and covered with 4ml of 26°C-27°C fusion medium (0.3M mannitol, 0.1mM MgSO₄, 0.05mM CaCl₂). The cells are then electrofused by application of a double direct current (DC) electrical pulse of 70-100V for about 15 μ s, approximately 1s apart. After fusion, the resultant fused reconstituted cells are then placed in a suitable medium until activation, eg., TCM-199 medium.

In a preferred method of cell fusion the donor animal cell is firstly attached to the enucleated oocyte. For example, a compound is selected to attach the animal cell to the enucleated oocyte to enable fusing of the animal

cell and enucleated oocyte membranes. The compound may be any compound capable of agglutinating cells. The compound may be a protein or glycoprotein capable of binding or agglutinating carbohydrate. More preferably the compound is a lectin. The lectin may be selected from the group including Concanavalin A, Canavalin A, Ricin, soybean lectin, lotus seed lectin and phytohemagglutinin (PHA). Preferably the compound is PHA.

10 In one preferred embodiment, the method of electrofusion described above also comprises a further fusion step, or the fusion step comprises described above comprises one donor animal cell and two or more enucleated oocytes. The double fusion method has the advantageous effect of

15 increasing the cytoplasmic volume of the reconstituted cell.

20 A reconstituted animal cell is typically activated by electrical and/or non-electrical means before, during, and/or after fusion of the nuclear donor and recipient oocyte (See, for example, Susko-Parrish et al., U.S. Pat. No. 5,496,720). Activation methods include:

- 25 1). Electric pulses;
- 2). Chemically induced shock;
- 3). Penetration by sperm;
- 4). Increasing levels of divalent cations in the oocyte by introducing divalent cations into the oocyte cytoplasm, eg., magnesium, strontium, barium or calcium, eg., in the form of an ionophore. Other methods of

30 increasing divalent cation levels include the use of electric shock, treatment with ethanol and treatment with caged chelators; and

35 5). Reducing phosphorylation of cellular proteins in the oocyte by known methods, eg., by the addition of kinase inhibitors, eg., serine-threonine kinase inhibitors, such as 6-dimethyl-aminopurine, staurosporine, 2-aminopurine, and sphingosine.

Alternatively, phosphorylation of cellular proteins may be inhibited by introduction of a phosphatase into the oocyte, eg., phosphatase 2A and phosphatase 2B.

- 5 The activated reconstituted animal cells, or embryos, are typically cultured in medium well known to those of ordinary skill in the art, and include, without limitation, TCM-199 plus 10% FSC, Tyrodes-Albumin-Lactate-Pyruvate (TALP), Ham's F-10 plus 10% FCS, synthetic
- 10 oviductal fluid ("SOF"), B2, CRLaa, medium and high potassium simplex medium ("KSOM").

- 15 The reconstituted cell may also be activated by known methods. Such methods include, eg., culturing the reconstituted cell at sub-physiological temperature, in essence by applying a cold, or actually cool temperature shock to the reconstituted cell. This may be most conveniently done by culturing the reconstituted animal cell at room temperature, which is cold relative to the physiological temperature conditions to which embryos are normally exposed. Suitable oocyte activation methods are the subject of U.S. Pat. No. 5,496,720, to Susko-Parrish *et al.*, herein incorporated by reference in its entirety.
- 20
- 25 The activated reconstituted animal cells may then be cultured in a suitable *in vitro* culture medium until the generation of cells and cell colonies. Culture media suitable for culturing and maturation of animal embryos are well known in the art. Examples of known media, which
- 30 may be used for bovine embryo culture and maintenance, include Ham's F-10 plus 10% FCS, TCM-199 plus 10% FCS, Tyrodes-Albumin-Lactate-Pyruvate (TALP), Dulbecco's Phosphate Buffered Saline (PBS), Eagle's and Whitten's media. One of the most common media used for the
- 35 collection and maturation of oocytes is TCM-199, and 1 to 20% serum supplement including fetal calf serum, newborn serum, estrual cow serum, lamb serum or steer serum. A

preferred maintenance medium includes TCM-199 with Earl salts, 10% FSC, 0.2mM Na pyruvate and 50 μ g/ml gentamicin sulphate. Any of the above may also involve co-culture with a variety of cell types such as granulosa cells, 5 oviduct cells, BRL cells and uterine cells and STO cells.

Afterward, the cultured reconstituted animal cell or embryos are preferably washed and then placed in a suitable media, e.g., TCM-199 medium containing 10% FCS 10 contained in well plates which preferably contain a suitable confluent feeder layer. Suitable feeder layers include, by way of example, fibroblasts and epithelial cells, e.g., fibroblasts and uterine epithelial cells derived from ungulates, chicken fibroblasts, murine (e.g., 15 mouse or rat) fibroblasts, STO and SI-m220 feeder cell lines, and BRL cells.

In one embodiment, the feeder cells comprise mouse embryonic fibroblasts. Preparation of a suitable 20 fibroblast feeder layers are well known in the art.

The reconstituted animal cells are cultured on the feeder layer until the reconstituted cells reach a size suitable for transferring to a recipient female, or for obtaining 25 cells which may be used to produce cells or cell colonies. Preferably, these reconstituted cells will be cultured until at least about 2 to 400 cells, more preferably about 4 to 128 cells, and most preferably at least about 50 cells. The culturing will be effected under suitable 30 conditions, i.e., about 39°C. and 5% CO₂, with the culture medium changed in order to optimise growth typically about every 2-5 days, preferably about every 3 days.

The methods for embryo transfer and recipient animal 35 management in the present invention are standard procedures used in the embryo transfer industry. Synchronous transfers are important for success of the

present invention, i.e., the stage of the nuclear transfer embryo is in synchrony with the estrus cycle of the recipient female. This advantage and how to maintain recipients are reviewed in Siedel, G. E., Jr. ("Critical

5 review of embryo transfer procedures with cattle" in Fertilization and Embryonic Development in Vitro (1981) L. Mastroianni, Jr. and J. D. Biggers, ed., Plenum Press, New York, N.Y., page 323), the contents of which are hereby incorporated by reference.

10

Briefly, blastocysts may be transferred non-surgically or surgically into the uterus of a synchronised recipient. Other medium may also be employed using techniques and media well-known to those of ordinary skill in the art. In

15 one procedure, cloned embryos are washed three times with fresh KSOM and cultured in KSOM with 0.1% BSA for 4 days and subsequently with 1% BSA for an additional 3 days, under 5% CO₂, 5% O₂ and 90% N₂ at 39°C. Embryo development is examined and graded by standard procedures known in the

20 art. Cleavage rates are recorded on day 2 and cleaved embryos are cultured further for 7 days. On day seven, blastocyst development is recorded and one or two embryos, pending availability of embryos and/or animals, is transferred non-surgically into the uterus of each

25 synchronised foster mother.

Foster mothers preferably are examined for pregnancy by rectal palpation or ultrasonography periodically, such as on days 40, 60, 90 and 120 of gestation. Careful

30 observations and continuous ultrasound monitoring (monthly) preferably is made throughout pregnancy to evaluate embryonic loss at various stages of gestation. Any aborted fetuses should be harvested, if possible, for DNA typing to confirm clone status as well as routine

35 pathological examinations.

The reconstituted animal cell, activated reconstituted

animal cell, fetus and animal produced during the steps of such method, and cells, nuclei, and other cellular components which may be harvested therefrom, are also asserted as embodiments of the present invention. It is 5 particularly preferred that the term animal produced be a viable animal.

The present invention can also be used to produce embryos, fetuses or offspring which can be used, for example, in 10 cell, tissue and organ transplantation. By taking a fetal or adult cell from an animal and using it in the cloning procedure a variety of cells, tissues and possibly organs can be obtained from cloned fetuses as they develop through organogenesis. Cells, tissues, and organs can be 15 isolated from cloned offspring as well. This process can provide a source of "materials" for many medical and veterinary therapies including cell and gene therapy. If the cells are transferred back into the animal in which the cells were derived, then immunological rejection is 20 averted. Also, because many cell types can be isolated from these clones, other methodologies such as hematopoietic chimerism can be used to avoid immunological rejection among animals of the same species as well as between species. 25 In one embodiment, the candidate gene will be a plant gene which is capable of producing hybrid vigour as discussed *supra*.

Traditionally a hybrid plant is produced by random event 30 by crossing one elite inbred plant with one or more other, genetically different and diverse, inbred plants. The crossing consists of taking the pollen from one inbred elite plant and transferring to the other elite inbred plant. The seed from crossing of two inbreds is a first 35 generation hybrid and is called a F_1 . The F_1 of commercially valuable inbreds have better yields, standability, and improvement in other important

characteristics than either of the parents.

In the present invention once a candidate gene has been identified it is isolated or synthesised and either 5 subcloned into an expression vector or transformed directly into a recipient plant.

There are many methods for transforming DNA segments into cells, but not all are suitable for delivering DNA to 10 plant cells. Suitable methods for use with the current invention are believed to include virtually any method by which DNA can be introduced into a cell, such as by direct delivery of DNA such as by PEG-mediated transformation of protoplasts (Omirulleh et al., 1993), by 15 desiccation/inhibition-mediated DNA uptake (Potrykus et al., 1985), by electroporation (U.S. Pat. No. 5,384,253, specifically incorporated herein by reference in its entirety), by agitation with silicon carbide fibers (Kleppl et al., 1990; U.S. Pat. No. 5,302,523, 20 specifically incorporated herein by reference in its entirety; and U.S. Pat. No. 5,464,765, specifically incorporated herein by reference in its entirety), by Agrobacterium-mediated transformation (U.S. Pat. No. 5,591,616 and U.S. Pat. No. 5,563,055; both specifically 25 incorporated herein by reference) and by acceleration of DNA coated particles (U.S. Pat. No. 5,550,318; U.S. Pat. No. 5,538,877; and U.S. Pat. No. 5,538,880; each specifically incorporated herein by reference in its entirety), etc. Through the application of techniques such 30 as these, plant cells may be stably transformed, and these cells developed into transgenic plants. In certain embodiments, acceleration methods are preferred and include, for example, microprojectile bombardment and the like.

35

Where one wishes to introduce candidate gene DNA by means of electroporation, it is contemplated that the method of

Krzyzek et al. (U.S. Pat. No. 5,384,253, incorporated herein by reference in its entirety) will be particularly advantageous. In this method, certain cell wall-degrading enzymes, such as pectin-degrading enzymes, are employed to

5 render the target recipient cells more susceptible to transformation by electroporation than untreated cells. Alternatively, recipient cells are made more susceptible to transformation by mechanical wounding.

10 To effect transformation by electroporation, one may employ either friable tissues, such as a suspension culture of cells or embryogenic callus or alternatively one may transform immature embryos or other organised tissue directly. In this technique, one would partially

15 degrade the cell walls of the chosen cells by exposing them to pectin-degrading enzymes (pectolyases) or mechanically wounding in a controlled manner. Examples of some species which have been transformed by electroporation of intact cells include maize (U.S. Pat.

20 No. 5,384,253; D'Halluin et al., 1992; Rhodes et al., 1995), wheat (Zhou et al., 1993), tomato (Hou and Lin, 1996), soybean (Christou et al., 1987), and tobacco (Lee et al., 1989).

25 One may also employ protoplasts for electroporation transformation of plants (Bates, 1994; Lazzeri, 1995). For example, the generation of transgenic soybean plants by electroporation of cotyledon-derived protoplasts is described by Dhir and Widholm in Intl. Patent Appl. Publ.

30 No. WO 9217598 (specifically incorporated herein by reference). Other examples of species for which protoplast transformation has been described include barley (Lazerri, 1995), sorghum (Battraw et al., 1991), maize (Bhattacharjee et al., 1997), wheat (He et al., 1994),

35 tomato (Tsukada, 1989), and soybean (Dhir et al., 1992).

A preferred method for delivering transforming candidate

gene DNA segments to plant cells in accordance with the invention is microparticle bombardment (U.S. Pat. No. 5,550,318; U.S. Pat. No. 5,538,880; U.S. Pat. No. 5,610,042; and PCT Application WO 94/09699; each of which is 5 specifically incorporated herein by reference in its entirety). In this method, particles may be coated with nucleic acids and delivered into cells by a propelling force. Exemplary particles include those comprised of tungsten, platinum, and preferably, gold. It is 10 contemplated that in some instances candidate gene DNA precipitation onto metal particles would not be necessary for DNA delivery to a recipient cell using microparticle bombardment. However, it is contemplated that particles may contain DNA rather than be coated with DNA. Hence, it 15 is proposed that DNA-coated particles may increase the level of DNA delivery via particle bombardment but are not, in and of themselves, necessary.

An illustrative embodiment of a method for delivering DNA 20 into plant cells by acceleration is the Biolistics Particle Delivery System, which can be used to propel particles coated with DNA or cells through a screen, such as a stainless steel or Nytex screen, onto a filter surface covered with plant cells cultured in suspension. 25 The screen disperses the particles so that they are not delivered to the recipient cells in large aggregates. It is believed that a screen intervening between the projectile apparatus and the cells to be bombarded reduces the size of projectiles aggregate and may contribute to a 30 higher frequency of transformation by reducing the damage inflicted on the recipient cells by projectiles that are too large.

Microprojectile bombardment techniques are widely 35 applicable, and may be used to transform virtually any plant species. Examples of species for which have been transformed by microprojectile bombardment include monocot

species such as maize (PCT Application WO 95/06128), barley (Ritala et al., 1994; Hensgens et al., 1993), wheat (U.S. Pat. No. 5,563,055, specifically incorporated herein by reference in its entirety), rice (Hensgens et al., 1993), oat (Torbet et al., 1995; Torbet et al., 1998), rye (Hensgens et al., 1993), sugarcane (Bower et al., 1992), and sorghum (Casa et al., 1993; Hagio et al., 1991); as well as a number of dicots including tobacco (Tomes et al., 1990; Busing and Benbow, 1994), soybean (U.S. Pat. No. 5,322,783, specifically incorporated herein by reference in its entirety), sunflower (Knittel et al. 1994), peanut (Singsit et al., 1997), cotton (McCabe and Martinell, 1993), tomato (VanEck et al. 1995), and legumes in general (U.S. Pat. No. 5,563,055, specifically incorporated herein by reference in its entirety).

For the bombardment, cells in suspension are concentrated on filters or solid culture medium. Alternatively, immature embryos or other target cells may be arranged on solid culture medium. The cells to be bombarded are positioned at an appropriate distance below the macroprojectile stopping plate. If desired, one or more screens may be positioned between the acceleration device and the cells to be bombarded.

Agrobacterium-mediated transfer is a widely applicable system for introducing genes into plant cells because the DNA can be introduced into whole plant tissues, thereby bypassing the need for regeneration of an intact plant from a protoplast. The use of Agrobacterium-mediated plant integrating vectors to introduce DNA into plant cells is well known in the art. See, for example, the methods described by Fraley et al., (1985), Rogers et al., (1987) and U.S. Pat. No. 5,563,055, specifically incorporated herein by reference in its entirety.

Agrobacterium-mediated transformation is most efficient in

dicotyledonous plants and is the preferable method for transformation of dicots, including *Arabidopsis*, tobacco, tomato, and potato. Indeed, while *Agrobacterium*-mediated transformation has been routinely used with dicotyledonous

5 plants for a number of years, it has only recently become applicable to monocotyledonous plants. Advances in *Agrobacterium*-mediated transformation techniques have now made the technique applicable to nearly all monocotyledonous plants. For example, *Agrobacterium*-

10 mediated transformation techniques have now been applied to rice (Hiei et al., 1997; Zhang et al., 1997; U.S. Pat. No. 5,591,616, specifically incorporated herein by reference in its entirety), wheat (McCormac et al., 1998), barley (Tingay et al., 1997; McCormac et al., 1998), and

15 maize (Ishidia et al., 1996).

Modern *Agrobacterium* transformation vectors are capable of replication in *E. coli* as well as *Agrobacterium*, allowing for convenient manipulations as described (Klee et al.,

20 1985). Moreover, recent technological advances in vectors for *Agrobacterium*-mediated gene transfer have improved the arrangement of genes and restriction sites in the vectors to facilitate the construction of vectors capable of expressing various polypeptide coding genes. The vectors

25 described (Rogers et al., 1987) have convenient multi-linker regions flanked by a promoter and a polyadenylation site for direct expression of inserted polypeptide coding genes and are suitable for present purposes. In addition, *Agrobacterium* containing both armed and disarmed Ti genes

30 can be used for the transformations. In those plant strains where *Agrobacterium*-mediated transformation is efficient, it is the method of choice because of the facile and defined nature of the gene transfer.

35 Transformation of plant protoplasts can be achieved using methods based on calcium phosphate precipitation, polyethylene glycol treatment, electroporation, and

combinations of these treatments (see, e.g., Potrykus et al., 1985; Lorz et al., 1985; Omirulleh et al., 1993; Fromm et al., 1986; Uchimiya et al., 1986; Callis et al., 1987; Marcotte et al., 1988).

5

Application of these systems to different plant strains depends upon the ability to regenerate that particular plant strain from protoplasts. Illustrative methods for the regeneration of cereals from protoplasts have been

10 described (Fujimara et al., 1985; Toriyama et al., 1986; Yamada et al., 1986; Abdullah et al., 1986; Omirulleh et al., 1993 and U.S. Pat. No. 5,508,184; each specifically incorporated herein by reference in its entirety).

15 Examples of the use of direct uptake transformation of cereal protoplasts include transformation of rice (Ghosh-Biswas et al., 1994), sorghum (Battraw and Hall, 1991), barley (Lazerri, 1995), oat (Zheng and Edwards, 1990) and maize (Omirulleh et al., 1993).

20 To transform plant strains that cannot be successfully regenerated from protoplasts, other ways to introduce DNA into intact cells or tissues can be utilised. For example, regeneration of cereals from immature embryos or explants can be effected as described (Vasil, 1989). Also, silicon

25 carbide fiber-mediated transformation may be used with or without protoplasting (Kaeppeler, 1990; Kaeppeler et al., 1992; U.S. Pat. No. 5,563,055, specifically incorporated herein by reference in its entirety). Transformation with this technique is accomplished by agitating silicon

30 carbide fibers together with cells in a DNA solution. DNA passively enters as the cells are punctured. This technique has been used successfully with, for example, the monocot cereals maize (PCT Application WO 95/06128, specifically incorporated herein by reference in its

35 entirety; Thompson, 1995) and rice (Nagatani, 1997).

Optimisation of Microprojectile Bombardment

For microprojectile bombardment transformation in accordance with the current invention, both physical and

5 biological parameters may be optimised. Physical factors are those that involve manipulating the DNA/microprojectile precipitate or those that affect the flight and velocity of either the macro- or microprojectiles. Biological factors include all steps

10 involved in manipulation of cells before and immediately after bombardment, such as the osmotic adjustment of target cells to help alleviate the trauma associated with bombardment, the orientation of an immature embryo or other target tissue relative to the particle trajectory,

15 and also the nature of the transforming DNA, such as linearized DNA or intact supercoiled plasmids. It is believed that pre-bombardment manipulations are especially important for successful transformation of immature embryos.

20 Accordingly, it is contemplated that one may wish to adjust various of the bombardment parameters in small scale studies to fully optimise the conditions. One may particularly wish to adjust physical parameters such as

25 DNA concentration, gap distance, flight distance, tissue distance, and helium pressure. It is further contemplated that the grade of helium may effect transformation efficiency. For example, differences in transformation efficiencies may be witnessed between bombardments using

30 industrial grade (99.99% pure) or ultra pure helium (99.999% pure), although it is not currently clear which is more advantageous for use in bombardment. One may also optimize the trauma reduction factors (TRFs) by modifying conditions which influence the physiological state of the

35 recipient cells and which may therefore influence transformation and integration efficiencies. For example, the osmotic state, tissue hydration and the subculture

stage or cell cycle of the recipient cells may be adjusted for optimum transformation.

Both physical and biological parameters for bombardment 5 may be addressed for further optimisation of ballistic transformation. Physical factors are those that involve manipulating the DNA/microprojectile precipitate or those that affect the flight and velocity of either the macro- or microprojectiles. Biological factors include all steps 10 involved in manipulation of cells immediately before and after bombardment. The pre-bombardment culturing conditions, such as osmotic environment, the bombardment parameters, and the plasmid configuration have been 15 adjusted to yield the maximum numbers of stable transformants.

(i) Physical Parameters

1. Gap Distance

20 The variable nest (macro holder) can be adjusted to vary the distance between the rupture disk and the macroprojectile, i.e., the gap distance. This distance can be varied from 0 to 2 cm. The predicted effects of a 25 shorter gap are an increase of velocity of both the macro- and microprojectiles, an increased shock wave (which leads to tissue splattering and increased tissue trauma), and deeper penetration of microprojectiles. Longer gap distances would have the opposite effects but may increase 30 viability and therefore the total number of recovered stable transformants.

2. Flight Distance

35 The fixed nest (contained within the variable nest) can be varied between 0.5 and 2.25 cm in predetermined 0.5 cm increments by the placement of spacer rings to adjust the

flight path traversed by the macroprojectile. Short flight paths allow for greater stability of the macroprojectile in flight but reduce the overall velocity of the microprojectiles. Increased stability in flight increases, 5 for example, the number of centered GUS foci. Greater flight distances (up to some point) increase velocity but also increase instability in flight. Based on observations, it is recommended that bombardments typically be done with a flight path length of about 1.0 10 cm to 1.5 cm.

3. Tissue Distance

Placement of tissue within the gun chamber can have 15 significant effects on microprojectile penetration. Increasing the flight path of the microprojectiles will decrease velocity and trauma associated with the shock wave. A decrease in velocity also will result in shallower penetration of the microprojectiles.

20

4. Helium Pressure

By manipulation of the type and number of rupture disks, pressure can be varied between 400 and 2000 psi within the 25 gas acceleration tube. Optimum pressure for stable transformation has been determined to be between 1000 and 1200 psi.

5. Coating of Microprojectiles.

30

For microprojectile bombardment, one will attach (i.e. "coat") DNA to the microprojectiles such that it is delivered to recipient cells in a form suitable for transformation thereof. In this respect, at least some of 35 the transforming DNA must be available to the target cell for transformation to occur, while at the same time during delivery the DNA must be attached to the microprojectile.

Therefore, availability of the transforming DNA from the microprojectile may comprise the physical reversal of bonds between transforming DNA and the microprojectile following delivery of the microprojectile to the target cell. This need not be the case, however, as availability to a target cell may occur as a result of breakage of unbound segments of DNA or of other molecules which comprise the physical attachment to the microprojectile. Availability may further occur as a result of breakage of bonds between the transforming DNA and other molecules, which are either directly or indirectly attached to the microprojectile. It further is contemplated that transformation of a target cell may occur by way of direct recombination between the transforming DNA and the genomic DNA of the recipient cell. Therefore, as used herein, a "coated" microprojectile will be one which is capable of being used to transform a target cell, in that the transforming DNA will be delivered to the target cell, yet will be accessible to the target cell such that transformation may occur.

Any technique for coating microprojectiles which allows for delivery of transforming DNA to the target cells may be used. Methods for coating microprojectiles which have been demonstrated to work well with the current invention have been specifically disclosed herein. DNA may be bound to microprojectile particles using alternative techniques, however. For example, particles may be coated with streptavidin and DNA end labelled with long chain thiol cleavable biotinylated nucleotide chains. The DNA adheres to the particles due to the streptavidin-biotin interaction, but is released in the cell by reduction of the thiol linkage through reducing agents present in the cell.

35

Alternatively, particles may be prepared by functionalising the surface of a gold oxide particle,

providing free amine groups. DNA, having a strong negative charge, binds to the functionalised particles.

Furthermore, charged particles may be deposited in controlled arrays on the surface of mylar flyer disks used 5 in the PDS-1000 Biolistics device, thereby facilitating controlled distribution of particles delivered to target tissue.

As disclosed above, it further is proposed, that the 10 concentration of DNA used to coat microprojectiles may influence the recovery of transformants containing a single copy of the transgene. For example, a lower concentration of DNA may not necessarily change the efficiency of the transformation, but may instead increase 15 the proportion of single copy insertion events. In this regard, approximately 1 ng to 2000 ng of transforming DNA may be used per each 1.8 mg of starting microprojectiles. In other embodiments of the invention, approximately 2.5 ng to 1000 ng, 2.5 ng to 750 ng, 2.5 ng to 500 ng, 2.5 ng 20 to 250 ng, 2.5 ng to 100 or 2.5 ng to 50 ng of transforming DNA may be used per each 1.8 mg of starting microprojectiles.

Various other methods may also be used to increase 25 transformation efficiency and/or increase the relative proportion of low-copy transformation events. For example, the inventors contemplate end-modifying transforming DNA with alkaline phosphatase or an agent which will blunt DNA ends prior to transformation. Still further, an inert 30 carrier DNA may be included with the transforming DNA, thereby lowering the effective transforming DNA concentration without lowering the overall amount of DNA used. These techniques are further described in U.S. patent application Ser. No. 08/995,451, filed Dec. 22, 35 1997, the disclosure of which is specifically incorporated herein by reference in its entirety.

(ii) Biological Parameters

Culturing conditions and other factors can influence the physiological state of the target cells and may have profound effects on transformation and integration efficiencies. First, the act of bombardment could stimulate the production of ethylene which could lead to senescence of the tissue. The addition of antiethylene compounds could increase transformation efficiencies.

Second, it is proposed that certain points in the cell cycle may be more appropriate for integration of introduced DNA. Hence synchronisation of cell cultures may enhance the frequency of production of transformants. For example, synchronisation may be achieved using cold treatment, amino acid starvation, or other cell cycle-arresting agents. Third, the degree of tissue hydration also may contribute to the amount of trauma associated with bombardment as well as the ability of the microprojectiles to penetrate cell walls.

The position and orientation of an embryo or other target tissue relative to the particle trajectory may also be important. For example, the PDS-1000 biolistics device does not produce a uniform spread of particles over the surface of a target petri dish. The velocity of particles in the centre of the plate is higher than the particle velocity at further distances from the centre of the petri dish. Therefore, it is advantageous to situate target tissue on the petri dish such as to avoid the centre of the dish, referred to by some as the "zone of death." Furthermore, orientation of the target tissue with regard to the trajectory of targets also can be important. It is contemplated that it is desirable to orient the tissue most likely to regenerate a plant toward the particle stream. For example, the scutellum of an immature embryo comprises the cells of greatest embryogenic potential and therefore should be oriented toward the particle stream.

It also has been reported that slightly plasmolyzed yeast cells allow increased transformation efficiencies (Armaleo et al., 1990). It was hypothesised that the altered 5 osmotic state of the cells helped to reduce trauma associated with the penetration of the microparticle. Additionally, the growth and cell cycle stage may be important with respect to transformation.

10 1. Osmotic Adjustment

It has been suggested that osmotic pre-treatment could potentially reduce bombardment associated injury as a result of the decreased turgor pressure of the plasmolyzed 15 cell. In a previous study, the number of cells transiently expressing GUS increased following subculture into both fresh medium and osmotically adjusted medium (PCT Application WO 95/06128, specifically incorporated herein by reference in its entirety). Pretreatment times of 90 20 minutes showed higher numbers of GUS expressing foci than shorter times. Cells incubated in 500 mOSM/kg medium for 90 minutes showed an approximately 3.5 fold increase in transient GUS foci than the control. Preferably, immature embryos are precultured for 4-5 hours prior to bombardment 25 on culture medium containing 12% sucrose. A second culture on 12% sucrose is performed for 16-24 hours following bombardment. Alternatively, type II cells are pretreated on 0.2M mannitol for 3-4 hours prior to bombardment. It is contemplated that pretreatment of cells with other 30 osmotically active solutes for a period of 1-6 hours may also be desirable.

2. Plasmid Configuration

35 In some instances, it will be desirable to deliver candidate gene DNA to cells that do not contain DNA sequences necessary for maintenance of the plasmid vector

in the bacterial host, eg., *E. coli*, such as antibiotic resistance genes, including but not limited to ampicillin, kanamycin, and tetracycline resistance, and prokaryotic origins of DNA replication. In such case, a DNA fragment

5 containing the transforming DNA may be purified prior to transformation. An exemplary method of purification is gel electrophoresis on a 1.2% low melting temperature agarose gel, followed by recovery from the agarose gel by melting gel slices in a 6-10 fold excess of Tris-EDTA buffer (10

10 mM Tris-HCl pH 8.0, 1 mM EDTA, 70°C.-72°C); frozen and thawed (37°C); and the agarose pelleted by centrifugation. A Qiagen Q-100 column then may be used for purification of DNA. For efficient recovery of DNA, the flow rate of the column may be adjusted to 40 ml/hr.

15

Isolated DNA fragments can be recovered from agarose gels using a variety of electroelution techniques, enzyme digestion of the agarose, or binding of DNA to glass beads (e.g., Gene Clean). In addition, HPLC and/or use of

20 magnetic particles may be used to isolate DNA fragments. As an alternative to isolation of DNA fragments, a plasmid vector can be digested with a restriction enzyme and this DNA delivered to maize cells without prior purification of the expression cassette fragment.

25

Tissue culture requires media and controlled environments. "Media" refers to the numerous nutrient mixtures that are used to grow cells *in vitro*, that is, outside of the intact living organism. The medium usually is a suspension

30 of various categories of ingredients (salts, amino acids, growth regulators, sugars, buffers) that are required for growth of most cell types. However, each specific cell type requires a specific range of ingredient proportions for growth, and an even more specific range of formulas

35 for optimum growth. Rate of cell growth also will vary among cultures initiated with the array of media that permit growth of that cell type.

Nutrient media is prepared as a liquid, but this may be solidified by adding the liquid to materials capable of providing a solid support. Agar is most commonly used for 5 this purpose. Bactoagar, Hazelton agar, Gelrite, and Gelgro are specific types of solid support that are suitable for growth of plant cells in tissue culture.

Some cell types will grow and divide either in liquid 10 suspension or on solid media. As disclosed herein, maize cells will grow in suspension or on solid medium, but regeneration of plants from suspension cultures requires transfer from liquid to solid media at some point in development. The type and extent of differentiation of 15 cells in culture will be affected not only by the type of media used and by the environment, for example, pH, but also by whether media is solid or liquid.

Recipient cell targets include, but are not limited to, 20 meristem cells, including the shoot apex (U.S. Pat. No. 5,736,369), Type I, Type II, and Type III callus, immature embryos and gametic cells such as microspores, pollen, sperm and egg cells. It is contemplated that any cell from 25 which a fertile plant may be regenerated is useful as a recipient cell. Type I, Type II, and Type III callus may be initiated from tissue sources including, but not limited to, immature embryos, seedling apical meristems, microspores and the like. Those cells which are capable of proliferating as callus are also recipient cells for 30 genetic transformation. The present invention provides techniques for transforming immature embryos and subsequent regeneration of fertile transgenic plants. Transformation of immature embryos obviates the need for long term development of recipient cell cultures. Pollen, 35 as well as its precursor cells, microspores, may be capable of functioning as recipient cells for genetic transformation, or as vectors to carry foreign DNA for

incorporation during fertilisation. Direct pollen transformation would obviate the need for cell culture. Meristematic cells (i.e., plant cells capable of continual cell division and characterised by an undifferentiated 5 cytological appearance, normally found at growing points or tissues in plants such as root tips, stem apices, lateral buds, etc.) may represent another type of recipient plant cell. Because of their undifferentiated growth and capacity for organ differentiation and 10 totipotency, a single transformed meristematic cell could be recovered as a whole transformed plant. In fact, it is proposed that embryogenic suspension cultures may be an in vitro meristematic cell system, retaining an ability for continued cell division in an undifferentiated state, 15 controlled by the media environment.

Cultured plant cells that can serve as recipient cells for transforming with desired DNA segments may be any plant cells including corn cells, and more specifically, cells 20 from *Zea mays* L. Somatic cells are of various types. Embryogenic cells are one example of somatic cells which may be induced to regenerate a plant through embryo formation. Non-embryogenic cells are those which typically will not respond in such a fashion. An example of non- 25 embryogenic cells are certain Black Mexican Sweet (BMS) corn cells.

The development of embryogenic calli and suspension cultures useful in the context of the present invention, 30 eg., as recipient cells for transformation, has been described in U.S. Pat. No. 5,134,074; and U.S. Pat. No. 5,489,520; each of which is incorporated herein by reference in its entirety.

35 Certain techniques may be used that enrich recipient cells within a cell population. For example, Type II callus development, followed by manual selection and culture of

friable, embryogenic tissue, generally results in an enrichment of recipient cells for use in, microprojectile transformation. Suspension culturing, particularly using the media disclosed herein, may improve the ratio of recipient to non-recipient cells in any given population. Manual selection techniques which can be employed to select recipient cells may include, eg., assessing cell morphology and differentiation, or may use various physical or biological means. Cryopreservation is also a 10 possible method of selecting for recipient cells.

Manual selection of recipient cells, eg., by selecting embryogenic cells from the surface of a Type II callus, is one means that may be used in an attempt to enrich for 15 recipient cells prior to culturing (whether cultured on solid media or in suspension). The preferred cells may be those located at the surface of a cell cluster, and may further be identifiable by their lack of differentiation, their size and dense cytoplasm. The preferred cells will 20 generally be those cells which are less differentiated, or not yet committed to differentiation. Thus, one may wish to identify and select those cells which are cytoplasmically dense, relatively unvacuolated with a high nucleus to cytoplasm ratio (e.g., determined by 25 cytological observations), small in size (e.g., 10-20 .mu.m), and capable of sustained divisions and somatic proembryo formation.

It is proposed that other means for identifying such cells 30 may also be employed. For example, through the use of dyes, such as Evan's blue, which are excluded by cells with relatively non-permeable membranes, such as embryogenic cells, and taken up by relatively differentiated cells such as root-like cells and snake 35 cells (so-called due to their snake-like appearance).

Other possible means of identifying recipient cells

include the use of isozyme markers of embryogenic cells, such as glutamate dehydrogenase, which can be detected by cytochemical stains (Fransz et al., 1989). However, it is cautioned that the use of isozyme markers including

5 glutamate dehydrogenase may lead to some degree of false positives from non-embryogenic cells such as rooty cells which nonetheless have a relatively high metabolic activity.

10 In one embodiment, the candidate gene, rather than producing hybrid vigour, will overcome, treat or at least alleviate the symptoms of disease. It will be appreciated by those skilled in the field that the experimental protocols outline above may be used to bring about this

15 outcome.

Generally, the terms "treating," "treatment" and the like are used herein to mean affecting an individual or subject, their tissue or cells to obtain a desired

20 pharmacological and/or physiological effect. The effect may be prophylactic in terms of completely or partially preventing the a disease or sign or symptom thereof, and/or may be therapeutic in terms of a partial or complete cure of disease. "Treating" as used herein

25 covers any treatment of, or prevention of disease in a plant or animal, and includes: (a) preventing the disease from occurring in a plant or animal that may be predisposed to the disease, but has not yet been diagnosed as having them; (b) inhibiting the disease, ie., arresting

30 its development; or (c) relieving or ameliorating the symptoms of the disease, ie., cause regression of the symptoms of the disease.

Once a plant or animal afflicted with a disease has been

35 diagnosed and a candidate gene, or combination of genes, has been identified then these genes or gene products may be administered to the plant or animal either using the

techniques described above with respect to hybrid vigour or using standard medical or agricultural techniques.

The terms "administration," "administering," and

5 "administered" are used herein interchangeably. For example, the candidate gene products may be administered orally including sublingual, topically, or parenterally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and

10 vehicles. The term parenteral as used herein includes subcutaneous injections, aerosol, intravenous, intramuscular, intrathecal, intracranial, injection or infusion techniques or rectal or vaginally.

15 Throughout the specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

20

IDENTIFICATION OF A NOVEL BIOCHEMICAL PATHWAY THAT FORMS HYBRID mRNA MOLECULES IN HETEROZYGOUS OFFSPRING

25 Recently, two allelic forms of the gene *DNMT2* have been described (Franchina et al., *Hum. Hered.* 52, 210 (2001)). *DNMT2* encodes an enzyme, which is involved in the process of DNA methylation. One of the alleles *DNMT2I* includes the nucleotides G in position 104 of exon 2 and C in position

30 50 of exon 4. The alternative allele, *DNMT2II* includes nucleotides A and T in these positions respectively. Thus the difference in the sequence of DNA within exons 2 and 4 between each of the two allelic forms of *DNMT2* permits the allelic origin of exons 2 and 4 in a final mRNA molecule

35 to be determined. These findings were used to test whether hybrid forms of mRNA can be formed in heterozygous offspring by incorporation of exons from each allele into

the same mature mRNA molecule, thereby generating novel polypeptide or protein molecules unique to heterozygous offspring.

5 In order to determine whether and how efficiently exons from each DNMT2 allele can be incorporated into the same mature RNA molecule after splicing of the primary transcript, mRNA was isolated from the peripheral blood leukocytes (PBL) of two subjects III 1 and III 2, who were
10 confirmed by segregation studies to be heterozygous for the two allelic forms of *DNMT2* (see Franchina et al., *Hum. Hered.* 52, 210 (2001)).

15 The mRNA was subjected to RT-PCR using primers, which amplified a region of cDNA of approximately 480bp that included exons 2 and 4 from *DNMT2*. The RT-PCR products of approximately 480bp in length from subjects III 1 and III 2 were cloned and a series of clones from each RT-PCR product were sequenced.

20 As shown in Table 1, inserts from 13 of 15 clones sequenced from subject III 1 reflected bi-allelic expression of *DNT2* and as expected, cis-assembly of exons 2 and 4 in the mature mRNA molecule. One of the clones
25 however, included a splice product that comprised exon 2 from the *DNMT2 I* allele and exon 4 from the *DNMT2 II* allele. A further clone comprised exon 2 from the *DNMT2 II* allele as well as exon 4 from the *DNMT2 I* allele. To assess the reproducibility of these findings and to
30 exclude the possibility that the two apparent hybrid mRNA molecules found in subject III 1 were consequential to some form of mitotic recombinational event, mRNA species were examined similarly from the PBL of subject III 2.

35 As shown in Table 1, 11 of 14 clones contained inserts, which reflected bi-allelic expression of *DNMT2* and cis-exonic assembly. The structure of a further 3 clones,

however, indicated that spliced mRNA molecules had been assembled. Two of them included exon 2 from the *DNMT2 II* allele and exon 4 from the *DNMT2 I* allele. The sequence of a further clone revealed that a spliced mRNA molecule 5 had been assembled by incorporation of exon 2 from the *DNMT2 I* allele and exon 4 from the *DNMT2 II* allele.

mRNA was then isolated from the PBL of a further two subjects, II 3 and II 4 (Franchina et al., *Hum. Hered.* 10 52,210 (2001)) who were confirmed to be homozygous for each of the two alternative allelic forms of *DNMT2*. An *in vitro* prepared mixture of equal quantities of mRNA from subjects II 3 and II 4 was treated in the same way as mRNA from subjects III 1 and III 2 used to exclude the 15 possibility that the hybrid mRNA *DNMT2* molecules found in the PBL of subjects III 1 and III 2 may have been generated *in vitro* due to template switching in the PCR stage of the RT-PCR due to the formation of truncated reverse transcripts. As shown in Table 1, no hybrid mRNA 20 molecules were found by reference to the sequence of inserts from 13 clones. Taken together, these findings establish that almost 20% of all spliced *DNMT2* RNA molecules comprise hybrid forms.

TABLE 1

Distribution of spliced *DNMT2* mRNA molecules in peripheral blood leukocytes according to the nucleotides present at 5 the polymorphic positions within exons 2 and 4.

		Subject		
<i>DNMT2</i> transcripts		III 1	III 2	Mix*
nt 104 of exon 2	nt 50 of exon 4			
G	C	5	5	8
A	T	8	6	5
G	T	1	1	0
A	C	1	2	0
total number of clones sequenced		15	14	13

Note: The genotypes *DNMT2 I/II* were confirmed in subjects III 1, III 2, and *DNMT2 I/I* and *DNMT2 II/II* in subjects II 10 3 and II 4 respectively by pedigree analysis.

*A mixture of mRNA from the homozygous *DNMT2 I* and *DNMT2 II* parents of subjects III 1, III 2, (II 3 and II 4) was 15 also subjected to RT-PCR and the products cloned and sequenced. No inserts were obtained which specified G-T or A-C spliced *DNMT2* mRNA molecules. These result confirm that our findings reflect the presence of an *in vivo* primary transcript splicing system involved in trans-exonic bi-allelic assembly of spliced mRNA molecules.

EXAMPLE 1

CONFIRMATION THAT HV AND HD[®] IS PRODUCED BY
THE NEW BIOCHEMICAL PATHWAY

5 The invention will now be further described by way of reference only to the following non-limiting examples. It should be understood, however, that the examples following are illustrative only, and should not be taken in any way as a restriction on the generality of the invention

10 described above. In particular, while the invention has been described in detail above, in relation to the identification of candidate genes using *DNMT2* alleles, it will be clearly understood that the findings herein are not limited to this gene or alleles.

15 HV occurs when an offspring displays an enhanced form of any particular biological phenotype when compared to expression of the same biological phenotype in either of its parents. Inventors believe that the invention

20 disclosed herein explains how an enhanced biological phenotype is generated in hybrid offspring by the formation of novel proteins or other gene products. The hybrid offspring must inherit allelic forms of the relevant genes which must differ according to the

25 structural criteria that they have defined *supra*.

EXAMPLE 2

MAMMALIAN ASL ALLELES

30 In humans, at least 5 different allelic forms of the gene which encodes the enzyme argininosuccinate lyase (ASL) have been identified. Some of them, *ASL(Q286R)*, *ASL(D87G)* and *ASL(A398D)*, for example, encode an inactive or mutant forms of ASL. Subjects that are homozygous for each of the mutant forms of ASL produce an inactive form of the enzyme

35 leading to the onset of a pathological condition known as argininosuccinic aciduria.

It is well recognised that in offspring who inherit certain different mutant forms of *ASL* from each of their affected parents, activity of *ASL* is restored. Different mutant alleles, when inherited in heterozygous form in

5 offspring in which *ASL* activity is restored (see Walker et al., *J. Biol. Chem.* 272, 6777 (1997)), are characterised by nucleotide changes which fulfil the structural criteria as defined *supra*.

10 As outlined below, inventors have proven that active *ASL* can be generated in offspring of affected parents by incorporation of wild-type encoding exons from each mutant allele into the same mRNA molecule by way of a newly identified biochemical pathway confirmed by studies (see

15 above) examining the structure of *DNMT2* mRNA species generated in subjects heterozygous for each of the two alternative allelic forms of *DNMT2*.

20 Previous studies have shown that when combinations of *ASL* mutants such as *ASL*(Q286R) and *ASL*(D87G) are inherited in heterozygous form, activity is restored. Therefore, mRNA was isolated from a subject who was proven to have inherited each of these two different allelic mutant forms of *ASL*. Total mRNA was subjected to RT-PCR using

25 oligonucleotide primers which spanned relevant exons. The RT-PCR product containing these exonic regions was cloned and sequenced.

30 The sequence of inserts from 14 clones generated from the RT-PCR product from the subject genotyped as *ASL*(Q286R) / (D87G) confirmed bi-allelic expression of *ASL* and cis-assembly of exons 4 and 9 into most mRNA molecules. Three clones however included inserts which comprised exon 4 from *ASL*(Q286R) and exon 9 from

35 *ASL*(D87G). Moreover, a further 2 clones included inserts which comprised exon 4 from *ASL*(D87G) and exon 9 from *ASL*(Q286R). The 6 recombinant or hybrid mRNA molecules

encode wild-type *ASL* enzyme accounting for restoration of enzyme activity.

EXAMPLE 3 PLANT ASL ALLELES

5

In plants, mutant *ASL* alleles have been found which encode an inactive enzyme. To determine whether the inventors proposed biochemical pathway generates recombinant mRNA molecules in plant hybrids in which wild-type enzyme activity is restored in offspring of affected parental plants, mRNA was isolated from a plant hybrid which is heterozygous for the two inactive *ASL* mutants *ASL III* and *ASL IV*. An RT-PCR product containing exons 3 and 5 from mRNA isolated from the hybrid plant was cloned and the 10 inserts from 18 of them were sequenced. The sequence of 15 inserts from 4 of the 18 clones confirm that hybrid mRNA molecules which encode the wild-type enzyme are assembled in plants which are heterozygous for two different mutant forms of the gene, leading to restoration of enzyme 20 activity.

EXAMPLE 4 DIABETES AS A MODEL FOR NEW BIOCHEMICAL PATHWAY

25 *GAD2* is well recognised as an important islet cell auto-antigen in patients suffering Type I diabetes. *GAD2* is encoded by multiple alleles, some of which are characterised by nucleotide changes in different exons which encode non-synonymous amino acids. We tested 30 whether heterozygosity for *GAD2* alleles which fit our structural criteria, was found more frequently in patients suffering Type I diabetes.

35 Examination of data generated from seminal studies revealed that heterozygosity for combinations of alleles which differ with respect to our structural criteria (and therefore synthesise novel forms of *GAD2*) is found more

frequently in patients suffering Type 1 diabetes. These findings are consistent with our hypothesis that in most cases, enhanced immunity against novel forms of GAD2 generated by our IP's new biochemical pathway, contributes 5 towards onset of Type I diabetes.

mRNA was extracted from pancreatic tissue obtained from a patient suffering from Type I diabetes. The patient was heterozygous for the GAD2 alleles GAD2(R12G), exon 1, and 10 GAD2(E232G), exon 3, which had nucleotide changes which complied with our IP's structural criteria, and had an anti GAD2 auto-antibody detected in their blood. mRNA was subjected to RT-PCR using oligonucleotide primers which spanned exons 1 and 3. The RT-PCR product including these 15 exons was cloned and sequenced.

The sequence of inserts of 12 clones confirmed bi-allelic expression of each of the two GAD2 alleles. A further 2 clones contained inserts which included exon 1 from the 20 GAD2(R12G) allele and exon 3 from the GAD2(E232G) allele. Two inserts which included exon 1 from the GAD2(E232G) allele and exon 3 from the GAD2(R12G) allele were also found. These findings confirm that a novel or hybrid form of GAD2 is synthesised in islet cells from a subject 25 suffering from Type I diabetes who has a high level of auto-antibody to GAD2 and who is heterozygous for different allelic forms of GAD2 that fulfil our IP's structural criteria.

30 THE ROLE OF GAD2 HETEROZYGOSITY IN AUTOANTIBODY INDUCTION

Most Patients suffering Type I diabetes have readily detectable levels of auto-antibody directed against GAD2, the most important auto-antigen in Type I diabetes. 35 Antibodies against GAD2 may be detected in the serum of patients suffering Type I diabetes prior to disease onset as well as in the serum of their asymptomatic sibs, albeit

at lower levels, indicating that other factors as well as GAD2 auto-antibodies are required for the onset of Type I diabetes.

5 In keeping with inventors findings and hypothesis that heterozygosity for GAD2 alleles which fulfil the structural criteria allows generation of hybrid forms of GAD2 that enhance the immune response against GAD2, auto-antibody levels should vary according to GAD2 genotype
10 even in non-Type I diabetic subjects. Results of a recent comprehensive study by Boutin et al., PLoS Biol. 1, 68 (2003) confirm that GAD2 auto-antibody levels are significantly higher in normal non-diabetic subjects as well as obese patients who are heterozygous for GAD2
15 alleles compared to the same groups of subjects and patients who are homozygous for the same GAD2 alleles. These findings strongly support inventors claim that novel polypeptides or proteins, formed by the novel biochemical pathway in subjects who are heterozygous for different
20 forms of alleles, which fulfil inventors structural criteria, synthesise auto-antibodies more readily than subjects who are homozygous for the same GAD2 alleles.

25

Dated this 3rd day of February 2004

PETER HAMILTON KAY

By their Patent Attorneys

30 GRIFFITH HACK

Fellows Institute of Patent and
Trade Mark Attorneys of Australia